The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK

TitleThe prevalence of darunavir-associated mutations in HIV-1-infected children in the UK
Publication TypeJournal Article
Year of Publication2012
AuthorsDonegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM
JournalAntivir Ther
Volume17
Pagination599-603
ISBN Number1359-6535
Accession Number22300840
Keywords*Drug Resistance, Viral, Anti-HIV Agents/*therapeutic use, Child, Darunavir, Great Britain/epidemiology, HIV Infections/*drug therapy/epidemiology/*virology, HIV-1/*drug effects/genetics, Humans, Mutation, Prevalence, Sulfonamides/*therapeutic use
Abstract

BACKGROUND: We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS: The prevalence of DRV RAMs, identified from IAS 2010 and Stanford, and the Stanford susceptibility score, were estimated in PI-naive and PI-experienced children in the Collaborative HIV Paediatric Study and the UK HIV Drug Resistance Database 1998-2008. Associations between type/duration of PI exposure and area under the viraemia curve on PI with the number of RAMs were investigated using multivariate Poisson regression. RESULTS: A total of 17/417 (4%) children with a resistance test when PI-naive had one IAS DRV RAM, and 1 had a Stanford mutation; none had multiple DRV RAMs. A total of 177 PI-experienced children had a test after a median 2.7 years (IQR 1.1-5.2) on PIs; 19 (11%) had one IAS DRV RAM, 7 (4%) had two RAMs, 1 (0.6%) had three RAMs and 1 (0.6%) had four RAMs. DRV RAMs were independently associated with increased years on a PI, a larger area under the viraemia curve since starting PIs, and any exposure to PIs other than lopinavir (all P

Short TitleAntiviral therapy
Alternate JournalAntiviral therapy